Salivary duct carcinoma: A clinical and histologic review with implications for trastuzumab therapy

Head and Neck

Volumn 29, Issue 10, 2007, Pages 907-912

  Nabili, Vishad ^a   Tan, Jesse W ^a   Bhuta, Sunita ^a   Sercarz, Joel A ^a   Head, Christian S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Breast; FISH; HER 2 neu; Herceptin; Salivary duct carcinoma

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ARTICLE; DRUG EFFICACY; FACIAL NERVE PARALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MALE; PAROTID GLAND; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SALIVARY GLAND CARCINOMA; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; METABOLISM; MIDDLE AGED; MORTALITY; PAGET NIPPLE DISEASE; SALIVARY GLAND TUMOR; TUMOR RECURRENCE;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, DUCTAL; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CHEMOTHERAPY, ADJUVANT; FACIAL PARALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS;

EID: 38449104762     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20614     Document Type: Article

References (26)

1. Kleinsasser O, Klein HJ, Hubner G. Salivary duct carcinoma: a group of salivary gland tumors analogous to mammary duct carcinoma (German). Arch Klin Exp Ohren Nasen Kehlkopfheilkd 1968;192:100-115.
2. Barnes EL Jr. Tumor pathology of the head and neck. In: 106th Semi-Annual CTTR Seminar: Tumors of the Head and Neck, Pittsburgh, PA; 1999. pp 8-12.
3. Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 2002;9:75-85.
4. Nabholtz JM, Reese DM, Lindsay MA, Riva A. HER-2-positive breast cancer: update on Breast Cancer International Research Group trials. Clin Breast Cancer 2002;3(Suppl 2):S75-S79.
5. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER-2. Drugs 2002;62:209-243.
6. Skalova A, Starek I, Vanecek T, et al. Salivary duct carcinoma: a group of salivary gland tumors analogous to mammary duct carcinoma (German). Arch Klin Exp Ohren Nasen Kehlkopfheilkd 1968;192:100-115.
7. Press MF, Slamon DJ, Flom KJ, Park J, Zhou JY, Bernstein L. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-3105.
8. Guzzo M, Di Palma S, Grandi C, Molinari R. Salivary duct carcinoma: clinical characteristics and treatment strategies. Head Neck 1997;19:126-133.
9. Lewis JE, McKinney B, Weiland L, Ferreiro J, Olsen K. Salivary duct carcinoma: clinicopathologic and immunohistochemical review of 26 cases. Cancer 1996;77:223-230.
10. Kapadia S, Barnes L. Expression of androgen receptor, gross cystic disease fluid protein, and CD44 in salivary duct carcinoma. Mod Pathol 1998;11:1033-1038.
11. Fan C-Y, Wang J, Barnes L. Expression of androgen receptor and prostatic specific markers in salivary duct carcinoma. Am J Surg Pathol 2000;24:579-586.
12. Fan C-Y, Melhem M, Hosal S, Grandis JR, Barnes EL. Expression of androgen receptor, epidermal growth factor receptor, and transforming growth factor alpha in salivary duct carcinoma. Arch Otolaryngol Head Neck Surg 2001;127:1075-1079.
13. Moriki T, Ueta S, Takahashi T, Mitani M, Ichien M. Salivary duct carcinoma: cytologic characteristics and application of androgen receptor immunostaining for diagnosis. Cancer 2001;93:344-350.
14. Slamon D, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER-2. N Engl J Med 2001;344:783-792.
15. Tan-Chiu E, Piccart M. Moving forward: Herceptin in the adjuvant setting. Oncology 2002;63(Suppl 1):57-63.
16. Bell R. What can we learn from Herceptin trials in metastatic breast cancer? Oncology 2002;63(Suppl 1):39-46.
17. Bell R. Ongoing trials with trastuzumab in metastatic breast cancer. Ann Oncol 2001;12(Suppl 1):S69-S73.
18. Treish I, Schwartz R, Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm 2000;57:2063-2079.
19. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001;37(Suppl 1):S18-S24.
20. Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol 2000;27(5, Suppl 9):20-26.
21. Vogel C, Cobleigh M, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
22. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002;29(3, Suppl 11):38-43.
23. Perez EA, Hortobagyi GN. Ongoing and planned adjuvant trials with trastuzumab. Semin Oncol 2000;27(6, Suppl 11):26-32; discussion 92-100.
24. Cobleigh MA, Vogel C, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
25. Agus D, Bunn P, Franklin W, Garcia M, Ozols RF. Her2/neu as a therapeutic target in non-small cell lung cancer, prostate cancer, and ovarian cancer. Semin Oncol 2000;27(Suppl 11):53-63.
26. Press MF, Guido S, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large prospective randomized clinical trials. Clin Cancer Res 2005;11:6598-6607.